280 related articles for article (PubMed ID: 20074047)
1. Strategies for the identification of ubiquitin ligase inhibitors.
Goldenberg SJ; Marblestone JG; Mattern MR; Nicholson B
Biochem Soc Trans; 2010 Feb; 38(Pt 1):132-6. PubMed ID: 20074047
[TBL] [Abstract][Full Text] [Related]
2. Strategies for the identification of novel inhibitors of deubiquitinating enzymes.
Goldenberg SJ; McDermott JL; Butt TR; Mattern MR; Nicholson B
Biochem Soc Trans; 2008 Oct; 36(Pt 5):828-32. PubMed ID: 18793145
[TBL] [Abstract][Full Text] [Related]
3. A patent review of the ubiquitin ligase system: 2015-2018.
Li X; Elmira E; Rohondia S; Wang J; Liu J; Dou QP
Expert Opin Ther Pat; 2018 Dec; 28(12):919-937. PubMed ID: 30449221
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic strategies within the ubiquitin proteasome system.
Eldridge AG; O'Brien T
Cell Death Differ; 2010 Jan; 17(1):4-13. PubMed ID: 19557013
[TBL] [Abstract][Full Text] [Related]
5. Screening for E3-ubiquitin ligase inhibitors: challenges and opportunities.
Landré V; Rotblat B; Melino S; Bernassola F; Melino G
Oncotarget; 2014 Sep; 5(18):7988-8013. PubMed ID: 25237759
[TBL] [Abstract][Full Text] [Related]
6. Ubiquitination and deubiquitination: Implications on cancer therapy.
Dagar G; Kumar R; Yadav KK; Singh M; Pandita TK
Biochim Biophys Acta Gene Regul Mech; 2023 Dec; 1866(4):194979. PubMed ID: 37633647
[TBL] [Abstract][Full Text] [Related]
7. The ubiquitin system, disease, and drug discovery.
Petroski MD
BMC Biochem; 2008 Oct; 9 Suppl 1(Suppl 1):S7. PubMed ID: 19007437
[TBL] [Abstract][Full Text] [Related]
8. Cullin 5-RING E3 ubiquitin ligases, new therapeutic targets?
Lamsoul I; Uttenweiler-Joseph S; Moog-Lutz C; Lutz PG
Biochimie; 2016 Mar; 122():339-47. PubMed ID: 26253693
[TBL] [Abstract][Full Text] [Related]
9. Mapping the interactome of HPV E6 and E7 oncoproteins with the ubiquitin-proteasome system.
Poirson J; Biquand E; Straub ML; Cassonnet P; Nominé Y; Jones L; van der Werf S; Travé G; Zanier K; Jacob Y; Demeret C; Masson M
FEBS J; 2017 Oct; 284(19):3171-3201. PubMed ID: 28786561
[TBL] [Abstract][Full Text] [Related]
10. Targeting the ubiquitin system in cancer therapy.
Hoeller D; Dikic I
Nature; 2009 Mar; 458(7237):438-44. PubMed ID: 19325623
[TBL] [Abstract][Full Text] [Related]
11. Drug discovery in the ubiquitin-proteasome system.
Nalepa G; Rolfe M; Harper JW
Nat Rev Drug Discov; 2006 Jul; 5(7):596-613. PubMed ID: 16816840
[TBL] [Abstract][Full Text] [Related]
12. Ubiquitin-protein ligases--novel therapeutic targets?
Robinson PA; Ardley HC
Curr Protein Pept Sci; 2004 Jun; 5(3):163-76. PubMed ID: 15180521
[TBL] [Abstract][Full Text] [Related]
13. Ubiquitin-proteasome system as a target for anticancer treatment-an update.
Kim YJ; Lee Y; Shin H; Hwang S; Park J; Song EJ
Arch Pharm Res; 2023 Jul; 46(7):573-597. PubMed ID: 37541992
[TBL] [Abstract][Full Text] [Related]
14. Ubiquitin-proteasome system (UPS) as a target for anticancer treatment.
Park J; Cho J; Song EJ
Arch Pharm Res; 2020 Nov; 43(11):1144-1161. PubMed ID: 33165832
[TBL] [Abstract][Full Text] [Related]
15. Patented small molecule inhibitors in the ubiquitin proteasome system.
Guédat P; Colland F
BMC Biochem; 2007 Nov; 8 Suppl 1(Suppl 1):S14. PubMed ID: 18047738
[TBL] [Abstract][Full Text] [Related]
16. Deubiquitylating enzymes and drug discovery: emerging opportunities.
Harrigan JA; Jacq X; Martin NM; Jackson SP
Nat Rev Drug Discov; 2018 Jan; 17(1):57-78. PubMed ID: 28959952
[TBL] [Abstract][Full Text] [Related]
17. The therapeutic potential of deubiquitinating enzyme inhibitors.
Colland F
Biochem Soc Trans; 2010 Feb; 38(Pt 1):137-43. PubMed ID: 20074048
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases.
Edelmann MJ; Nicholson B; Kessler BM
Expert Rev Mol Med; 2011 Nov; 13():e35. PubMed ID: 22088887
[TBL] [Abstract][Full Text] [Related]
19. The ubiquitin-proteasome system and cardiovascular disease.
Powell SR; Herrmann J; Lerman A; Patterson C; Wang X
Prog Mol Biol Transl Sci; 2012; 109():295-346. PubMed ID: 22727426
[TBL] [Abstract][Full Text] [Related]
20. The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.
Tundo GR; Sbardella D; Santoro AM; Coletta A; Oddone F; Grasso G; Milardi D; Lacal PM; Marini S; Purrello R; Graziani G; Coletta M
Pharmacol Ther; 2020 Sep; 213():107579. PubMed ID: 32442437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
